Current Immunotherapy Approaches in Non-Hodgkin Lymphomas

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F20%3A10419655" target="_blank" >RIV/00216208:11110/20:10419655 - isvavai.cz</a>

Alternative codes found

RIV/00023736:_____/20:00013141 RIV/00064165:_____/20:10419655

Result on the web

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=ibtouRvf2S" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=ibtouRvf2S</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3390/vaccines8040708" target="_blank" >10.3390/vaccines8040708</a>

Result language

angličtina

Original language name

Current Immunotherapy Approaches in Non-Hodgkin Lymphomas

Original language description

Non-Hodgkin lymphomas (NHLs) are lymphoid malignancies of B- or T-cell origin. Despite great advances in treatment options and significant improvement of survival parameters, a large part of NHL patients either present with a chemotherapy-refractory disease or experience lymphoma relapse. Chemotherapy-based salvage therapy of relapsed/refractory NHL is, however, capable of re-inducing long-term remissions only in a minority of patients. Immunotherapy-based approaches, including bispecific antibodies, immune checkpoint inhibitors and genetically engineered T-cells carrying chimeric antigen receptors, single-agent or in combination with therapeutic monoclonal antibodies, immunomodulatory agents, chemotherapy or targeted agents demonstrated unprecedented clinical activity in heavily-pretreated patients with NHL, including chemotherapy-refractory cases with complex karyotype changes and other adverse prognostic factors. In this review, we recapitulate currently used immunotherapy modalities in NHL and discuss future perspectives of combinatorial immunotherapy strategies, including patient-tailored approaches.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30205 - Hematology

Project

Result was created during the realization of more than one project. More information in the Projects tab.

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2020

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Vaccines

ISSN

2076-393X

e-ISSN

—

Volume of the periodical

8

Issue of the periodical within the volume

4

Country of publishing house

CH - SWITZERLAND

Number of pages

45

Pages from-to

708

UT code for WoS article

000601779800001

EID of the result in the Scopus database

2-s2.0-85096710395